Trial Profile
Follow-up of Myocardial T1 Relaxation Time in Patients With Anderson Fabry Disease (AFD): Impact of Treatment by Agalsidase Alpha (Replagal®)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 May 2020
Price :
$35
*
At a glance
- Drugs Agalsidase alfa (Primary)
- Indications Fabry's disease
- Focus Diagnostic use
- Acronyms MyFABT1
- 25 May 2018 Planned End Date changed from 1 Dec 2020 to 1 Mar 2020.
- 25 May 2018 Planned primary completion date changed from 1 Dec 2020 to 1 Mar 2020.
- 25 May 2018 Status changed from not yet recruiting to recruiting.